Zinaida Perić, MD, PhD, University Hospital Centre Zagreb, Zagreb, Croatia, gives an overview of her talk on advances in the management of chronic graft-versus-host disease (GvHD). Recent improvements in the treatment of chronic GvHD include antithymocyte globulin (ATG) and post-transplant cyclophosphamide. Clinical trials are currently evaluating the use of post-transplant cyclophosphamide in combination with cyclosporine compared to standard immunosuppression with cyclosporine and mycophenolate mofetil (MMF) and have shown that adding post-transplant cyclophosphamide significantly reduces chronic GvHD and leads to improvements in GvHD-free relapse-free survival. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.
Advances in chronic GvHD management
Теги
Speaker: Zinaida PerićInstitution: University Hospital Centre ZagrebEvent: IACH 2021Format: InterviewField: TransplantationField: TreatmentField: PerspectivesField: Clinical PracticeMedicines: Anti-thymocyte GlobulinMedicines: CyclophosphamideMedicines: CyclosporineMedicines: Mycophenolate Mofetilchronicgraft-versus-host diseaseGvHDHOVON